149 related articles for article (PubMed ID: 38662226)
21. Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era.
Takagi T; Fukuda H; Ishihara H; Yoshida K; Kondo T; Kobayashi H; Iizuka J; Okumi M; Ishida H; Omae K; Tanabe K
Urol Oncol; 2020 May; 38(5):515-520. PubMed ID: 32146128
[TBL] [Abstract][Full Text] [Related]
22. Extent of lymph node dissection improves overall survival in pT3N0 non-metastatic renal cell carcinoma patients treated with radical nephrectomy: a propensity score-based analysis.
Wei Y; Wang M; Jin Y; Zhou C; Lyu J
World J Urol; 2020 Jun; 38(6):1579-1585. PubMed ID: 31065795
[TBL] [Abstract][Full Text] [Related]
23. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience.
De Gobbi A; Biasoni D; Catanzaro M; Nicolai N; Piva L; Stagni S; Torelli T; Procopio G; Verzoni E; Grassi P; Colecchia M; Paolini B; Spreafico C; Marchianò A; Salvioni R
Tumori; 2018 Oct; 104(5):388-393. PubMed ID: 28085177
[TBL] [Abstract][Full Text] [Related]
24. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
[TBL] [Abstract][Full Text] [Related]
25. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.
Sun M; Meyer CP; Karam JA; de Velasco G; Chang SL; Pal SK; Trinh QD; Choueiri TK
Eur J Surg Oncol; 2018 Sep; 44(9):1439-1445. PubMed ID: 29935840
[TBL] [Abstract][Full Text] [Related]
26. Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry.
Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
Cancer Med; 2019 Jul; 8(7):3401-3410. PubMed ID: 31070307
[TBL] [Abstract][Full Text] [Related]
27. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma.
Eggener SE; Yossepowitch O; Kundu S; Motzer RJ; Russo P
J Urol; 2008 Sep; 180(3):873-8; discussion 878. PubMed ID: 18635225
[TBL] [Abstract][Full Text] [Related]
28. Extended hepatic metastasectomy for renal cell carcinoma-new aspects in times of targeted therapy: a single-center experience over three decades.
Beetz O; Söffker R; Cammann S; Oldhafer F; Vondran FWR; Imkamp F; Klempnauer J; Kleine M
Langenbecks Arch Surg; 2020 Feb; 405(1):97-106. PubMed ID: 31938833
[TBL] [Abstract][Full Text] [Related]
29. Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites.
Jakubowski CD; Vertosick EA; Untch BR; Sjoberg D; Wei E; Palmer FL; Patel SG; Downey RJ; Strong VE; Russo P
J Surg Oncol; 2016 Sep; 114(3):375-9. PubMed ID: 27338155
[TBL] [Abstract][Full Text] [Related]
30. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.
Ristau BT; Handorf EA; Cahn DB; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2018 Oct; 124(19):3839-3848. PubMed ID: 30207380
[TBL] [Abstract][Full Text] [Related]
31. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
Bedke J; Heide J; Ribback S; Rausch S; de Martino M; Scharpf M; Haitel A; Zimmermann U; Pechoel M; Alkhayyat H; Shariat SF; Dombrowski F; Stenzl A; Burchardt M; Klatte T; Kroeger N
BJU Int; 2018 Jan; 121(1):84-92. PubMed ID: 28803448
[TBL] [Abstract][Full Text] [Related]
32. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.
Verbiest A; Couchy G; Job S; Caruana L; Lerut E; Oyen R; de Reyniès A; Tosco L; Joniau S; Van Poppel H; Van Raemdonck D; Van Den Eynde K; Wozniak A; Zucman-Rossi J; Beuselinck B
Eur Urol; 2018 Oct; 74(4):474-480. PubMed ID: 29463434
[TBL] [Abstract][Full Text] [Related]
33. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
35. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
[TBL] [Abstract][Full Text] [Related]
36. [Survival analysis of interferon-alpha on locally advanced clear cell renal cell carcinoma after radical nephrectomy].
Xia J; Li X; Chen XQ; Li X; Zeng H; Wei Q; Zhang P; Zhu YC
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):91-4. PubMed ID: 22455140
[TBL] [Abstract][Full Text] [Related]
37. Is there a role for partial nephrectomy in patients with metastatic renal cell carcinoma?
Hellenthal NJ; Mansour AM; Hayn MH; Schwaab T
Urol Oncol; 2013 Jan; 31(1):36-41. PubMed ID: 21396834
[TBL] [Abstract][Full Text] [Related]
38. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
39. Spinal metastasectomy of renal cell carcinoma: A 16-year single center experience with a minimum 3-year follow-up.
Kato S; Murakami H; Demura S; Nambu K; Fujimaki Y; Yoshioka K; Kawahara N; Tomita K; Tsuchiya H
J Surg Oncol; 2016 Apr; 113(5):587-92. PubMed ID: 26846902
[TBL] [Abstract][Full Text] [Related]
40. Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma.
You D; Lee C; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2331-8. PubMed ID: 27553579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
